Search alternatives:
patent decrease » point decrease (Expand Search), content decreased (Expand Search), greatest decrease (Expand Search)
small decrease » small increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
_ patent » _ patient (Expand Search), _ parent (Expand Search), _ patients (Expand Search)
patent decrease » point decrease (Expand Search), content decreased (Expand Search), greatest decrease (Expand Search)
small decrease » small increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
_ patent » _ patient (Expand Search), _ parent (Expand Search), _ patients (Expand Search)
-
1
-
2
-
3
Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc
Published 2025“…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
Data Sheet 1_Improvement of pulmonary edema and respiratory status after transcatheter PDA closure in the smallest and most premature infants.docx
Published 2025“…</p>Results<p>40% of patients weaned respiratory support. x-ray haziness change was not significantly different between groups (p = 0.086), however trended toward significance. 59% had decreased haziness and 16% had a marked decrease. Smaller, younger infants were more likely to wean support and have improved edema.…”
-
18
-
19
-
20